Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia

Ing S Tiong; Richard Dillon; Adam Ivey; Tse-Chieh Teh; Phillip Nguyen; Nicholas Cummings; David C Taussig; Annie-Louise Latif; Nicola E Potter; Manohursingh Runglall; Nigel H Russell; Kavita Raj; Anthony P Schwarer; Chun Yew Fong; Andrew P Grigg; Andrew H Wei

doi:10.1111/bjh.16722

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia

Ing S Tiong, Richard Dillon, Adam Ivey, Tse-Chieh Teh, Phillip Nguyen, Nicholas Cummings, David C Taussig, Annie-Louise Latif, Nicola E Potter, Manohursingh Runglall, Nigel H Russell, Kavita Raj, Anthony P Schwarer, Chun Yew Fong, Andrew P Grigg, Andrew H Wei

Medical & Molecular Genetics

Department of Clinical Haematology, Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Vic., Australia.
St. John's Institute of Dermatology; Division of Genetics & Molecular Medicine; Faculty of Life Sciences and Medicine; King's College London; NIHR Biomedical Research Centre at Guy's and St. Thomas' Hospitals and King's College London; Guy's Hospital; King's College London; London, UK.
Monash University
Department of Haematology, Royal Marsden Hospital, London, UK.
NHS Greater Glasgow and Clyde
Department of Medical and Molecular Genetics, School of Basic & Medical Biosciences, King's College London, London, UK.
King's College London; Guy's & St Thomas' NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

68 Citations (Scopus)

Abstract

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD- ) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD.

Original language	English
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.16722
Publication status	E-pub ahead of print - 26 May 2020

Keywords

AML
MRD
NPM1
venetoclax

Access to Document

10.1111/bjh.16722

Cite this

Tiong, I. S., Dillon, R., Ivey, A., Teh, T.-C., Nguyen, P., Cummings, N., Taussig, D. C., Latif, A.-L., Potter, N. E., Runglall, M., Russell, N. H., Raj, K., Schwarer, A. P., Fong, C. Y., Grigg, A. P., & Wei, A. H. (2020). Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. British Journal of Haematology. Advance online publication. https://doi.org/10.1111/bjh.16722

@article{0d84fa92f77b4f65ac090ad3fd59f936,

title = "Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia",

abstract = "Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD- ) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD.",

keywords = "AML, MRD, NPM1, venetoclax",

author = "Tiong, {Ing S} and Richard Dillon and Adam Ivey and Tse-Chieh Teh and Phillip Nguyen and Nicholas Cummings and Taussig, {David C} and Annie-Louise Latif and Potter, {Nicola E} and Manohursingh Runglall and Russell, {Nigel H} and Kavita Raj and Schwarer, {Anthony P} and Fong, {Chun Yew} and Grigg, {Andrew P} and Wei, {Andrew H}",

note = "{\textcopyright} 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2020",

month = may,

day = "26",

doi = "10.1111/bjh.16722",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

}

Tiong, IS, Dillon, R, Ivey, A, Teh, T-C, Nguyen, P, Cummings, N, Taussig, DC, Latif, A-L, Potter, NE, Runglall, M, Russell, NH, Raj, K, Schwarer, AP, Fong, CY, Grigg, AP & Wei, AH 2020, 'Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia', British Journal of Haematology. https://doi.org/10.1111/bjh.16722

TY - JOUR

T1 - Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia

AU - Tiong, Ing S

AU - Dillon, Richard

AU - Ivey, Adam

AU - Teh, Tse-Chieh

AU - Nguyen, Phillip

AU - Cummings, Nicholas

AU - Taussig, David C

AU - Latif, Annie-Louise

AU - Potter, Nicola E

AU - Runglall, Manohursingh

AU - Russell, Nigel H

AU - Raj, Kavita

AU - Schwarer, Anthony P

AU - Fong, Chun Yew

AU - Grigg, Andrew P

AU - Wei, Andrew H

PY - 2020/5/26

Y1 - 2020/5/26

N2 - Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD- ) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD.

AB - Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1mut measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CRMRD- ) without transplantation. Six of seven patients with molecular relapse/progression achieved CRMRD- after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1mut MRD.

KW - AML

KW - MRD

KW - NPM1

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85085567944&partnerID=8YFLogxK

U2 - 10.1111/bjh.16722

DO - 10.1111/bjh.16722

M3 - Article

C2 - 32458446

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this